There was also a 65% relative reduction in COVID-related medical visits (95% CI 24.4-83.8) with nirmatrelvir-ritonavir versus ...

A higher possibility of finding viruses that cause Covid-19 was linked to patients who had taken the antiviral drugs.

COVID-19 antivirals, specifically, have become hard to access for some patients. Many requirements accompany the distribution of the drugs to patients, and for a good reason. Accessing antivirals ...

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...

Paxlovid significantly shortened the time to symptom relief (median, 13 vs 15 days; hazard ratio [HR], 1.27) and resolution (16 vs 19 days; HR, 1.20) through 28 days and cut the number of ...

Business which accounts for close to one-third of group sales also took in €437m in dividends from subsidiaries dotted ...

NORTH CAROLINA (WTVD) -- The CDC is warning that viruses will spread over the next couple of months. Agency leaders are ...

COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, ...

Other companies are developing oral antivirals for COVID-19, notably Merck & Co and Ridgeback Biotherapeutics' molnupiravir and Pfizer's PF-07321332, which have both just moved into phase 3 ...

The former public health official who filed a whistleblower complaint against the Trump administration is ringing the alarm ...

Onconova Therapeutics Inc ( (TRAW) ) has released its Q3 earnings. Here is a breakdown of the information Onconova Therapeutics Inc presented ...

Illinois health officials receive flu and COVID-19 vaccinations, emphasizing the importance of immunization before the ...